Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
266.25
-2.7 (-1%)
Market Cap: 34.34 Bil
Enterprise Value: 33.21 Bil
PE Ratio: 0
PB Ratio: 1,065.00
GF Score: 78/100 
Alnylam Pharmaceuticals Inc at Cowen Health Care Conference Transcript
Mar 08, 2023 / 07:10PM GMT
Release Date Price:
$190.41
(-2.02%)
Ritu Subhalaksmi Baral
TD Cowen, Research Division - MD & Senior Biotechnology Analyst
Thank you everyone for joining us for the Alnylam Pharmaceuticals Fireside Chat at the 43rd Annual TD Cowen Conference. I'm covering analyst, Ritu Baral, and with us today from Alnylam, we have Pushkal Garg, CMO; as well as Rena Denoncourt, VP and TTR program lead at Alnylam. Welcome Rena and Pushkal. Good to have you back.
Rena N. Denoncourt
Alnylam Pharmaceuticals, Inc. - VP & TTR Franchise Lead
Thank you.
Pushkal P. Garg
Alnylam Pharmaceuticals, Inc. - Chief Medical Officer and Executive VP of Development & Medical Affairs
Thank you.
Questions & Answers
Ritu Subhalaksmi Baral
TD Cowen, Research Division - MD & Senior Biotechnology Analyst
All right, let's start with your sNDA. You know where I'm going with this. Have you had any more recent communication with the FDA about the sNDA for ATTR-CM? Have you been notified of any emerging review issues? You
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers